Fewer days of radiation may control brain tumors just as well
NCT ID NCT07167134
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial compares two radiation schedules for people with 1 to 5 brain metastases from cancers like melanoma, kidney, or sarcoma. One group gets radiation on days 1, 3, and 5; the other on days 1, 2, and 3. The goal is to see if the shorter schedule controls tumor growth as well or better at 6 months, while reducing treatment burden.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy
What this could lead to
If successful, this could offer a more convenient and equally effective radiotherapy schedule for patients with hard-to-treat brain metastases.
What could go wrong
This is a phase 3 trial, but it only compares two radiation schedules; it does not test a new drug or cure. The benefit may be modest, and results may not apply to all brain metastasis types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICANS
Strasbourg, France
Contact Phone: •••-•••-•••• Email: •••••@•••••